Member Info for draft

ZUCHWIL, SWITZERLAND - Merrick, a leading global manufacturer of biotechnology products and recognized innovator in automated medical robotic systems, today announced a definitive agreement to acquire AI Medical Systems, GmbH., founded in 2016 by Silicon Valley entrepreneur Philip Odegard. Merrick will acquire all of the outstanding capital stock of AI Medical, which is privately-owned and based in Zurich, Switzerland, for approximately CHF 2.3 Billion ($2,318,515,000 USD). The acquisition marks the second successful Artificial Intelligence buyout in Philip Odegard’s expansive technology portfolio. Odegard’s more notable early investments include the likes of Silicon Valley’s UBER, Facebook and Tesla.

The AI Medical transaction, subject to customary closing conditions, including receipt of certain regulatory approvals, is expected to be completed in the fourth calendar quarter of 2018. AI Medical is a technology-led company, focused solely on the design and manufacture of dependable, life improving Artificial Intelligence and machine learning software coupled with robotic hardware that are affordable for caregivers worldwide. One key way Artificial Intelligence benefits is with diagnostic and imaging tools, like MRIs and CT and PET scans. Algorithms can be trained to accurately measure all of the lymph nodes from a cancer patient's CT scan to see if they're changing size. It's a huge job that algorithms can do much more quickly than humans.

Merrick’s acquisition of AI Medical Systems includes their proprietary first-to-market artificial intelligence algorithms and machine learning – the science of getting computers to act without being programmed by humans. One such algorithm is called a neural network because it can learn and improve performance on its own like the human brain, but can work much faster. Collectively, these powerful acquired tools will help find disease almost before a patient is symptomatic, treat it early, and achieve a higher survival rate with less patient suffering and at reduced cost.

AI Medical’s products are sold in Europe and more than 115 countries worldwide, with a surging demand in the United Arab Emirates. “This acquisition is consistent with Merrick’s strategy to expand into adjacencies and invest in product categories where it can develop global competitive advantages,” said Amanda Eriksen, President, Robotics & Monitoring Systems, Merrick. “AI Medical’s products and technology complement the Company’s current portfolio of healthcare biotechnology solutions and will broaden our software platform for patients around the world, particularly in emerging markets.” Assuming a closing in the fourth calendar quarter of 2018, Merrick does not expect this transaction to have a material impact on its fiscal 2018 sales, operating margin or earnings per share. Once the transaction has been completed, Merrick will report the AI Medical business as part of its Software & Automated Machinery product line in the Medical D

David is a truly inspiring senior executive whom delivered exceptional results through his excellent leadership values. The proven financial results of the Hospital Group is a true testament of David's executive leadership style. He has an exceptional ability to develop successful business partnerships with our suppliers and customers.

President & CEO, Founder
Tenaxis Medical Inc
October 2004 – November 2011 7 years 2 months
Tenaxis Medical Inc was founded in 2004 and develops and manufactures surgical sealants. Its first product, ArterX , a surgical sealant, was launched in Europe in 2009, was awarded a PMA and will be launched in the USA in 2013. Raised over $25M from private investors.
Tenaxis Medical Inc was sold to The Medicines Company (NASDAQ:MDCO) for $168M in May 2014;

some serious big players in this industry like Fujifilm, Siemens healthcare, Toshiba, Philips, GE healthcare, Facebook medical, Google healthcare, Hitachi medical. these guys have got serious money to spend.

dunno. but the costs here are low and they are predicting $250,000 per quarter revenue from 2019 once they get IB products all onto DICOM viewer. look at the recent revenue figures. they had done double the revenue in half the time. revenue of £1.5 mill for FY 2019 won't surprise me. add a few bolt on acquisitions might even go higher. also we are standard list and not aim. being standard list has got to attract better institutions to invest. there's a lot happening in the space.

In recent weeks the Company has experienced a significant increase in the level of interest in the Company's licences and has welcomed a number of new parties, including established North Sea operators, into its data room. While providing these new entrants sufficient time to evaluate the opportunities available, the Company is continuing discussions with several parties who have previously indicated an interest in the assets. Whilst there can be no guarantee that any of these discussions will have a positive conclusion, the Company remains confident of being able to secure a successful outcome from the farm out process and looks forward to providing a further update in due course

the KEY is these new people who have arrived in the data room

https://sbcnews.co.uk/sportsbook/2018/09/25/metric-gaming-secures-10-million-series-a-funding-us-vision/

Updating the market, Metric Gaming reveals that its series A was led by New York-based family investment fund RDA Ventures LLC.

The series A funds will be used to help establish Metric Gaming as the go-to sportsbook platform and data services provider for the liberalised US sports betting market.

Martin de Knijff, Metric Gaming founder and CEO, said: “This investment will accelerate Metric Gaming’s plans to capitalize on the substantial market opportunities arising as states across the U.S. continue to legalize sports betting.

“Metric’s B2B value proposition – a turnkey, mobile-optimized solution that includes the transaction platform, front-end, trading, operations, risk management, product and unique content – is backed by pedigree and expertise built on both sides of the Atlantic, and will enable operators to quickly and efficiently capture market share.

Backing the investment, David Broser, President of RDA Ventures, said: “The combination of Metric’s product suite, services and management talent made this an easy investment for us.

“Metric is uniquely positioned as a sports betting B2B provider with advanced expertise that’s rare in the U.S., and we’re excited to be on the ground floor with such a compelling player in the nascent legalized U.S. market.”

Nektan hasn’t been left behind; the AIM company partnered up with US firm Metric Gaming a couple of weeks after the Supreme Court’s decision and Metric’s betting platform has now been integrated into the Evolve platform.

The company was also contracted by a “major tier-one operator” to design a white label betting game which is due to be launched in-venue in the current (second) quarter.

“Our North America division is making progress and is due to go live shortly with a tier-one operator,” said interim chief executive Gary Shaw.

http://www.proactiveinvestors.co.uk/companies/news/206264/nektan-well-positioned-to-attack-us-betting-market-as-it-reports-record-quarterly-performance-206264.html

Really undervalued here and we are Main Market and not aim like the other UK listed companies.

Scientific Digitial £37m
Polarean £13m
Ixico £12m
feedback £5m
IQ-AI £3m

I think IQ-AI with its buy and build strategy, TB in charge, low free float, All eyes on medical AI space, I can see multiples return here

BenevolentAI

BenevolentTech, part of the biotech business BenevolentAI, is developing an advanced AI platform to help scientists make new discoveries and redefine how they use the data available to them to drive innovation.

The technology is built on a deep learning judgement system that generates usable knowledge from vast amounts of information in scientific papers, patents, clinical trial information and from structured data sets. The technological goal is to augment human judgment so technology could assist the creative processes that characterise the very best scientists.

BenevolentAI is hoping to combine the power of machine brains with expert human brains to enable previously impossible scientific discoveries.

Cambridge Cognition is a neuroscience-focused digital health company which develops products and services with the aim of better understanding, detecting and treating conditions that affect brain health. It creates cognitive research technologies for mobile, wearable and online platforms which have the potential to accelerate new treatment development, improve research efficiency and measure cognitive health and wellbeing in patients on a global scale.

The company’s technology can measure digital cognitive biomarkers to track the improvement or decline in health of patients with conditions such as Alzheimer’s, Parkinson’s, depression, schizophrenia and ADHD. Its customers include global pharmaceutical and biotechnology companies, contract research organisations and academic research institutions.

DeepMind Technologies

Founded in September 2010, DeepMind Technologies is a British AI company. It was acquired by Google in 2014 but is still has its headquarters in London. The company is a self-proclaimed world leader in AI research and its application in areas such as healthcare and energy.

The DeepMind Applied team has collaborated with clinicians in the NHS with the aim of delivering better care for numerous conditions that affect millions of people worldwide, including cancer. It aims to use AI to radically improve healthcare but also believes the scientific advances being made could tackle other global problems, such as climate change, by creating a quicker platform to find solutions.

BenevolentAI

BenevolentTech, part of the biotech business BenevolentAI, is developing an advanced AI platform to help scientists make new discoveries and redefine how they use the data available to them to drive innovation.

The technology is built on a deep learning judgement system that generates usable knowledge from vast amounts of information in scientific papers, patents, clinical trial information and from structured data sets. The technological goal is to augment human judgment so technology could assist the creative processes that characterise the very best scientists.

BenevolentAI is hoping to combine the power of machine brains with expert human brains to enable previously impossible scientific discoveries.

Earlier this year, British Prime Minister Theresa May announced plans to increase the use of data and artificial intelligence (AI) to transform the diagnosis of chronic diseases in Britain.

The plans involve using emerging technologies to cross-reference patient genetics, habits and medical records with national data so that cancer can be easier to detect in its early stages. It is hoped this will result in at least 50,000 people each year receiving an earlier diagnosis of prostate, ovarian, lung or bowel cancer. May also stressed that successful implementation of the plans could create a whole new industry around AI in healthcare, potentially leading to new jobs.

With investment likely to increase and the government throwing its support behind AI in healthcare, the UK medical technology industry looks set to grow. But who are the star UK performers in the field of AI-enhanced health technology? Below are some of the top UK medical technology companies currently dominating the healthcare AI field.

Skin Analytics

This computer vision company aims to make the diagnosis of melanoma easier, making it exactly the kind of company the government is looking to support, with the AI initiative’s aim of 22,000 fewer people dying from cancer each year by 2033.

Skin Analytics builds a digital history of a patient’s skin so that any potentially cancerous changes, such as new skin lesions or moles, can be tracked. Patients can use the Skin Analytics smartphone app, called 4ev, for the tracking of their skin. The technology uses algorithms to measure how the skin is changing based on smartphone images taken by the individual. Treatment options can then be identified, evaluated and informed across a range of consumer health and clinical skin conditions.

Babylon Health

Founded by British entrepreneur Ali Parsa in 2013, Babylon is a mobile healthcare app and healthcare service provider, self-described as a convenient way to access NHS healthcare. It allows healthcare professionals to have virtual conversations with patients via text messages and videos and continues to build on its AI capabilities, such as diagnosis by AI. Patients can receive referrals, prescriptions, order test kits and sick notes and book appointments with local facilities through the service.

Babylon says it covers all NHS primary care services including the management of acute and chronic diseases. It current only works in partnership with healthcare practices in London but aims to expand. In April 2017, Babylon Health announced it had raised around £50m to develop its AI diagnosis tool, which the company said could reduce the cost of a consultation by as much as 80%.

Cambridge Cognition

Cambridge Cognition is a neuroscience-focused digital health company which develops products and services with the aim of better understanding, detecting and treating conditions that affect brain health. It creates cognitive research technologies for mobile, wearable and online pl

https://www.medicaldevice-network.com/digital-disruption/ai/ones-watch-top-uk-based-medical-technology-companies/

The UK is set to have the highest number of planned and announced crude and natural gas projects in the North Sea over the next seven years, according to a report by GlobalData.

The report titled ‘H2 2018 Production and Capital Expenditure Outlook for Key Planned Upstream Projects in the North Sea – Equinor ASA Leads in Total Oil and Gas Production’ considers projected production and capital expenditure for planned upstream projects in the North Sea between 2018 and 2025.

By 2025, around 67 crude and natural gas projects are anticipated to come online in the North Sea. Of these, 21 are planned projects with identified development plans while the remaining 46 are early-stage announced projects at conceptual stage and are expected to be approved.

Aggregate crude and condensate production from key projects in the North Sea in 2025 is estimated to be about 1,327.4 thousand barrels of oil per day, while total gas output will be around 1,924.4 million cubic feet per day.

Among countries, the UK assumes the leadership role in terms of number of planned oil and gas projects with 11 projects, while Norway and the Netherlands occupy the subsequent places with eight and two projects, respectively.

The UK also has the highest number of announced projects with 25, followed by Norway with 18 and the Netherlands with two.

“The UK also has the highest number of announced projects with 25, followed by Norway with 18 and the Netherlands with two.”
Among operators, Equinor Energy has the highest operatorship with nine planned and announced projects, followed by Aker BP and Equinor UK with six and four projects, respectively.

During the outlook period, capital expenditure to bring the planned projects online in the North Sea is projected to be around $18.9bn, while announced projects will have $24.2bn.

In terms of capex, Norway leads among countries with spending of around $12.8bn by 2025. The UK follows with capex spending of $5.6bn.

Meanwhile, the report stated that the UK and Norway will have the highest capex in terms of announced projects with spending of $14.6bn and $8.4bn, respectively.

Among companies, Equinor leads in terms of spending on planned projects with $6.4bn followed by Lundin Petroleum and Petoro with $2.2bn and $1.9bn, respectively.

In terms of spending on early-stage announced projects, Bridge Petroleum 4 ($4.7bn), Aker BP ($2.2bn), and Whalsay Energy ($2.1bn) are the highest spenders.

a few more recently and opened 2 long spreadbets.

wasnt having a go lol. just stating fact. anyway who cares. might as well average down.

you sold for a loss. the end.

this is the hot space right now in medical AI.